CIK 0001706431 · Large accelerated filer
Vir Biotechnology, Inc.
Sign in to watch- Ticker
- VIR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 812730369
- Phone
- 415-906-4324
- Business address
- 1800 OWENS STREET, SUITE 900, SAN FRANCISCO, CA, 94158
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $41,939
- in 1 filing, $42K under 10b5-1 plans
Net −$41,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 46 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-24 | SCANGOS GEORGE A Director | Sale 10b5-1 | −10,056 | $9.45 | $95K | 698,239 |
| 2025-02-24 | HANLY ANN M. EVP & Chief Technology Officer | Sale 10b5-1 | −14,168 | $9.45 | $134K | 117,901 |
| 2025-02-24 | Sabatini Brent SVP, Chief Accounting Officer | Sale 10b5-1 | −1,562 | $9.45 | $15K | 46,627 |
| 2025-02-24 | De Backer Marianne Chief Executive Officer | Sale 10b5-1 | −16,122 | $9.45 | $152K | 849,217 |
| 2025-02-24 | de Verneuil Vanina EVP and General Counsel | Sale 10b5-1 | −5,140 | $9.45 | $49K | 86,833 |
| 2025-02-22 | O'Byrne Jason EVP & Chief Financial Officer | Grant or award 10b5-1 | +40,000 | 115,000 | ||
| 2025-02-22 | O'Byrne Jason EVP & Chief Financial Officer | Grant or award · Stock Option (Right to Buy) 10b5-1 | +80,000 | 80,000 | ||
| 2025-02-22 | Eisner Mark EVP and Chief Medical Officer | Grant or award 10b5-1 | +40,000 | 115,000 | ||
| 2025-02-22 | Eisner Mark EVP and Chief Medical Officer | Grant or award · Stock Option (Right to Buy) 10b5-1 | +80,000 | 80,000 | ||
| 2025-02-22 | Sabatini Brent SVP, Chief Accounting Officer | Grant or award 10b5-1 | +20,000 | 48,189 | ||
| 2025-02-22 | Sabatini Brent SVP, Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) 10b5-1 | +40,000 | 40,000 | ||
| 2025-02-22 | De Backer Marianne Chief Executive Officer | Grant or award 10b5-1 | +240,000 | 865,339 | ||
| 2025-02-22 | De Backer Marianne Chief Executive Officer | Grant or award · Stock Option (Right to Buy) 10b5-1 | +480,000 | 480,000 | ||
| 2025-02-22 | de Verneuil Vanina EVP and General Counsel | Grant or award 10b5-1 | +35,000 | 91,973 | ||
| 2025-02-22 | de Verneuil Vanina EVP and General Counsel | Grant or award · Stock Option (Right to Buy) 10b5-1 | +70,000 | 70,000 | ||
| 2025-02-18 | SCANGOS GEORGE A Director | Sale 10b5-1 | −10,964 | $9.81 | $108K | 708,295 |
| 2025-02-13 | Sabatini Brent SVP, Chief Accounting Officer | Sale 10b5-1 | −1,562 | $9.15 | $14K | 28,189 |
| 2025-01-08 | SATO VICKI L Director | Sale 10b5-1 | −10,960 | $12.52 | $137K | 1,312,391 |
| 2024-12-02 | de Verneuil Vanina EVP and General Counsel | Sale | −76 | $8.22 | $625 | 56,973 |
| 2024-11-15 | O'Byrne Jason EVP & Chief Financial Officer | Grant or award 10b5-1 | +75,000 | 75,000 |
Page 7 of 54 · 1,063 trades